EPIC SCIENCES RAISES $43M IN FIRST CLOSE OF SERIES F FINANCING TO ADVANCE COMPREHENSIVE PROFILING FOR METASTATIC CANCER PATIENTS

/PRNewswire/ -- Epic Sciences, Inc. ("Epic" or "Epic Sciences"), a privately held diagnostics company, has completed a $43 million first close of its Series F...

Related Keywords

Roche Bioscience ,Lloyd Sanders ,Epic Sciences Inc ,Epic Or Sciences ,Perkinelmer ,Prnewswire Epic Sciences Inc ,Epic Sciences ,Corning Inc ,Ge Healthcare ,Epic Science ,Capital Partners ,Blue Ox Healthcare Partners ,Deerfield Management ,James Rothman Phd ,Healthcare Advisory Board ,Nobel Laureate ,Chief Scientist ,Richard Eglen Phd ,Senior Advisor ,Sterling Professor ,Cell Biology ,Yale University School ,Comprehensive Cancer ,Banking Amp Financial Services ,Medical Equipment ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Biotechnology ,Venture Capital ,